INNOGEN-B (02591) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results

Bulletin Express

Mar 10

Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) has scheduled a board meeting for Monday, 23 March 2026. According to the official announcement released in Shanghai on 10 March 2026, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and authorise their publication.

The notice was issued under the signature of Chairman Dr. Wang Qinghua. As of the announcement date, the board consists of:

• Executive Directors: Dr. Wang Qinghua, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing • Non-executive Directors: Mr. Ho Kyung Shik and Mr. Heng Lei • Independent Non-executive Directors: Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony

The company has confirmed that Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited assume no responsibility for the contents of the announcement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1103949350"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103949350\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103949350?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103949350","market":"us","top_or_hot":-1,"title":"INNOGEN-B (02591) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results","media":"Bulletin Express","content":"<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) has scheduled a board meeting for Monday, 23 March 2026. According to the official announcement released in Shanghai on 10 March 2026, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and authorise their publication.</p>\n<p>The notice was issued under the signature of Chairman Dr. Wang Qinghua. As of the announcement date, the board consists of:</p>\n<p>• Executive Directors: Dr. Wang Qinghua, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing  \n• Non-executive Directors: Mr. Ho Kyung Shik and Mr. Heng Lei  \n• Independent Non-executive Directors: Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony</p>\n<p>The company has confirmed that Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited assume no responsibility for the contents of the announcement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B (02591) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B (02591) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-10 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) has scheduled a board meeting for Monday, 23 March 2026. According to the official announcement released in Shanghai on 10 March 2026, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and authorise their publication.</p>\n<p>The notice was issued under the signature of Chairman Dr. Wang Qinghua. As of the announcement date, the board consists of:</p>\n<p>• Executive Directors: Dr. Wang Qinghua, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing  \n• Non-executive Directors: Mr. Ho Kyung Shik and Mr. Heng Lei  \n• Independent Non-executive Directors: Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony</p>\n<p>The company has confirmed that Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited assume no responsibility for the contents of the announcement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1103949350","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103949350","pubTimestamp":1773132241,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) has scheduled a board meeting for Monday, 23 March 2026. According to the official announcement released in Shanghai on 10 March...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"INNOGEN-B(02591)定于2026年3月23日召开董事会批准2025财年业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) has scheduled a board meeting for Monday, 23 March 2026. According to the official announcement released in Shanghai on 10 March 2026, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and authorise their publication.\nThe notice was issued under the signature of Chairman Dr. Wang Qinghua. As of the announcement date, the board consists of:\n• Executive Directors: Dr. Wang Qinghua, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing  \n• Non-executive Directors: Mr. Ho Kyung Shik and Mr. Heng Lei  \n• Independent Non-executive Directors: Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony\nThe company has confirmed that Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited assume no responsibility for the contents of the announcement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}